Kamada (KMDA) Stock: Buy, Sell, or Hold?
KMDA - Kamada Ltd
$7.77
0.04 (0.52%)
▲
5d:
+0.13%
30d:
-12.0%
90d:
+11.16%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
15d
Get Alerted When KMDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: KMDA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: KMDA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.79
Based on 12.4% avg growth
INTRINSIC VALUE TODAY
$9.19
15.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KMDA is currently trading at $7.77, which is considered slightly low relative to its 30-day fair value range of $7.75 to $8.61. The stock's valuation (Forward PE: 13.5) is in line with its historical norms (14.4). Remarkably, the market is currently pricing in an annual earnings decline of 2.2% over the next few years. This pessimistic expectation contrasts with the company's recent 23.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, KMDA is in a strong uptrend. The price is approaching resistance at $8.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KMDA scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.50 (+73.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KMDA is in a strong uptrend. The price is approaching resistance at $8.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KMDA scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.50 (+73.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.75 -
$8.61
Company Quality Score
70/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (74/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 73.7% below Wall St target ($13.50)
- BULLISH: Bottoming setup score 74/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$7.75 -
$8.61
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$7.46
Resistance Level
$8.00
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.47
Wall Street Target
$13.50
(+73.7%)
Revenue Growth (YoY)
22.7%
Earnings Growth (YoY)
23.1%
Profit Margin
11.6%
Valuation Discount vs History
-2.2% cheaper
PE vs Historical
13.5 vs 14.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.2%
(market-implied from PE analysis)
1-Year Target
$7.60
(-2%)
2-Year Target
$7.43
(-4%)
3-Year Target
$7.27
(-7%)
3-Yr Target (if PE normalizes)
(PE: 13→14)
$7.77
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 20.8%)
$20.18
(+160%)
Base:
(SPY PE: 13.5, Growth: 20.8%)
$13.69
(+76%)
Bear:
(PE: 11.5, Growth: 20.8%)
$11.64
(+50%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 20.34 | Current EPS (TTM): $0.38
Bull Case
$12.90
(+66%)
Analyst growth 51.8%, PE expands to 22.4
Base Case
$11.73
(+51%)
Market implied 51.8%, PE stable at 20.3
Bear Case
$5.26
(-32%)
Severe decline -20.0%, PE contracts to 17.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.5 to 14.4
Stabilization Target:
$8.30
(+6.9%)
PE Expansion Potential:
+6.9%
Share & Embed Analysis
Last updated: October 24, 2026 3:02 AM ET
Data refreshes hourly during market hours. Next update: 4:02 AM
Data refreshes hourly during market hours. Next update: 4:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KMDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
